Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Mining and Functional Validation (R01 Clinical Trial Not Allowed)
ID: 356035Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $350K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356035

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-26-001.html
Timeline
    Description

    The National Institutes of Health (NIH), through its National Institute on Drug Abuse (NIDA), is offering a funding opportunity titled the Single Cell Opioid Responses in the Context of HIV (SCORCH) Program, aimed at supporting research on the molecular responses of individual cells related to HIV and substance use disorders (SUD). The program seeks to fund projects that involve data mining of single cell datasets to identify key cellular components and validate their roles in HIV and SUD responses, utilizing innovative techniques such as machine learning and epigenomic manipulations. With an anticipated budget of $3 million over two years, the NIH plans to fund six to seven projects annually, requiring applicants to submit a Plan for Enhancing Diverse Perspectives (PEDP) to promote inclusivity in research. Interested applicants should note that the application period opens on February 19, 2025, and closes on March 20, 2026, with inquiries directed to grantsinfo@nih.gov for further information.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-DA-26-001.html
    The National Institutes of Health (NIH), through its National Institute on Drug Abuse (NIDA), announces a funding opportunity titled the Single Cell Opioid Responses in the Context of HIV (SCORCH) Program. This initiative aims to support research exploring the molecular responses of individual cells related to HIV and substance use disorders (SUD), focusing on the functional validation of relevant data mined from single cell datasets. The program encourages applications that utilize diverse techniques including machine learning and epigenomic manipulations. Eligible applicants include higher education institutions and nonprofit organizations, with an anticipated budget of $3 million over two years to fund six to seven projects per year. The application requires a Plan for Enhancing Diverse Perspectives (PEDP), emphasizing teamwork and inclusivity. Important dates include an application open date of February 19, 2025, and an expiration date of March 20, 2026. Applications will be reviewed based on scientific merit, innovation, and researchers' expertise, following NIH's peer review process.
    Similar Opportunities
    Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Mining and Functional Validation (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity titled "Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Mining and Functional Validation (R01 Clinical Trial Not Allowed)." This initiative aims to support projects focused on data mining single cell datasets to identify relevant cell types, transcripts, enhancers, or transcriptional networks associated with HIV and Substance Use Disorders (SUD), as well as to conduct functional validation studies to confirm their biological roles. The program emphasizes innovation and interdisciplinary collaboration to advance therapeutic pathways for HIV and SUD, with a total funding commitment of approximately $3 million anticipated across six to seven projects each fiscal year. Interested applicants must submit their proposals by March 19, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)" aimed at supporting innovative research that addresses the intersection of HIV and substance use. This initiative invites applications from individual researchers and research teams to develop projects that can lead to new prevention, treatment, and care strategies for individuals affected by both conditions, with a requirement for a detailed research plan and preliminary data. A total budget of $3.0 million is available for funding one to two awards, with individual project budgets capped at $1.5 million per fiscal year, and applications are due by February 12, 2027. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to consult with NIDA program staff early in the application process.
    High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)" aimed at supporting innovative research at the intersection of HIV and substance use. This initiative seeks proposals that address critical gaps in understanding and improving health outcomes for individuals living with HIV who also face substance use disorders, requiring detailed research plans and preliminary data from both individual researchers and research teams. NIH plans to allocate approximately $3 million annually for three to five awards over three years, with applications due by January 11, 2025, and a strong emphasis on enhancing diverse perspectives through an inclusion plan. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-024.html.
    Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Exploratory Clinical Neuroscience Research on Substance Use Disorders" (R61/R33), aimed at supporting innovative clinical research that explores the neurobiological mechanisms underlying substance use disorders (SUD). This initiative encourages applications that investigate neural circuitry and cognitive processes affecting substance use behavior, particularly in the context of the ongoing public health crisis related to SUDs, including the opioid epidemic. The R61/R33 mechanism allows for up to five years of funding, divided into an initial two-year R61 phase and a potential three-year R33 phase, contingent upon meeting specified milestones. Interested applicants can find more information and submit proposals by the application due date of March 13, 2026, and may contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Accelerating the Pace of Substance Use Research Using Existing Data (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity titled "Accelerating the Pace of Substance Use Research Using Existing Data." This initiative invites applications that propose innovative analyses of existing social science, behavioral, administrative, and neuroimaging data to investigate the etiology and epidemiology of substance use behaviors and related disorders, including HIV prevention and health service utilization. The program aims to leverage public datasets to enhance understanding of substance use trajectories and effective prevention strategies, particularly focusing on underrepresented populations and health disparities. A total funding commitment of $2 million is available for fiscal year 2026, with applications due by January 25, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)" aimed at supporting research into effective interventions for substance use disorders (SUDs) and overdose. This cooperative agreement encourages applications for preclinical and clinical studies focusing on pharmacotherapies, device-based treatments, digital therapeutics, and behavioral interventions, with the goal of advancing these interventions towards regulatory approval or clinical adoption. The funding amount can reach up to $3 million, and applications are due by 5:00 PM local time, with multiple submission cycles from October 2025 to August 2028. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Integrated Functional Mapping and Molecular Profiling of Cell Ensembles Encoding the Effects of Addictive Substances in Rodents (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Institute on Drug Abuse (NIDA), has announced a funding opportunity titled "Integrated Functional Mapping and Molecular Profiling of Cell Ensembles Encoding the Effects of Addictive Substances in Rodents." This initiative aims to support innovative research that utilizes scalable technologies to investigate the cellular responses associated with substance use disorders in rodent models, focusing on integrating neural activity metrics with molecular profiles to enhance understanding of addiction-related neurobehavioral processes. The total funding available is $2 million, with individual grants not exceeding $700,000 in direct costs per year for a project period of up to five years, and proposals must adhere to NIH’s data sharing policies. Interested applicants can find more information and submit inquiries via email to grantsinfo@nih.gov, with the application deadline set for February 23, 2026.
    Mitochondrial-associated Mechanisms of Neuropathological and Immunodeficient Aging in the Context of HIV and SUD (R01 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Mitochondrial-associated Mechanisms of Neuropathological and Immunodeficient Aging in the Context of HIV and SUD," aimed at researching the interplay between mitochondrial function, aging, HIV infection, and substance use disorders (SUD). This initiative seeks to uncover protective and pathogenic mechanisms that could lead to the development of targeted therapies to improve health outcomes for individuals aging with HIV and addiction issues. Approximately $3 million in funding is available, with anticipated awards ranging from three to six grants, and a Plan for Enhancing Diverse Perspectives (PEDP) is required from applicants. The application process will commence in February 2025, with a submission deadline of March 10, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-26-009.html.
    Establishing a Center for the Advancement of Substance Use Disorder (SUD) Pharmacotherapeutics through Training and Preclinical Support
    National Institutes of Health
    The National Institutes of Health (NIH) is seeking to establish a Center for the Advancement of Substance Use Disorder (SUD) Pharmacotherapeutics through a Cooperative Agreement aimed at enhancing the development of new pharmacotherapeutics for SUD. The Center will focus on educating researchers in formal product development and providing technical and financial support for initial experiments, with an emphasis on creating a product development curriculum and fostering collaborations within the research community. This initiative is crucial for advancing drug addiction research and supporting the translation of innovative concepts into practical applications. The estimated total program funding is $3 million, with one award expected, and interested parties can contact Dr. Tam Nguyen at Tam.Nguyen@nih.gov or (301) 451-1203 for further information. The estimated synopsis post date is November 21, 2025, with applications expected to close on January 27, 2026, and the project anticipated to start on September 1, 2026.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Basic Experimental Studies with Humans Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Basic Experimental Studies with Humans Required)," aimed at advancing research on non-invasive brain stimulation (NIBS) as a treatment for substance use disorders (SUDs). This initiative encourages innovative proposals that explore novel NIBS targets and neurobiological responses, with a focus on understanding the mechanisms underlying SUDs through clinical trials involving human subjects. The NIH plans to allocate $1.5 million annually over three years to fund approximately six grants, with applications due by January 16, 2024. Interested applicants can find more information and guidance on the required Plan for Enhancing Diverse Perspectives (PEDP) at the provided link, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.